Barcoding Technology for Multiplexed Analysis of Metastatic Ability In Vivo
Philip Dujardin1, Barbara M Grüner2
1Department of Medical Oncology, West German Cancer Center, University Hospital Essen at the University of Duisburg-Essen, Essen, Germany.
Methods in Molecular Biology (Clifton, N.J.)
|March 20, 2021
Summary
This study introduces a DNA barcoding screening platform to test drugs for their ability to stop cancer metastasis in mice. High-throughput compound screening using next-generation sequencing enables efficient analysis of metastatic seeding.
Area of Science:
- Biotechnology
- Cancer Research
- Pharmacology
Background:
- DNA barcoding offers precise tracking of cell populations without biomarkers.
- In vivo screening platforms are crucial for understanding complex biological processes like metastasis.
- High-throughput screening accelerates drug discovery and development.
Purpose of the Study:
- To develop and validate a multiplexed in vivo screening platform using DNA barcoding.
- To interrogate compound libraries for their effects on metastatic seeding in a high-throughput manner.
- To enable quantitative analysis of anti-metastatic drug efficacy in vivo.
Main Methods:
- Utilizing DNA barcoding technology for quantitative, biomarker-free cell tracking.
- Implementing a multiplexed in vivo screening system in mice.
- Applying next-generation sequencing (NGS) for high-throughput data analysis.
- Screening up to 96 compounds and controls simultaneously for their impact on metastatic ability.
Main Results:
- Demonstrated the feasibility of a DNA barcoding-based platform for in vivo screening.
- Successfully quantified the effects of multiple compounds on metastatic seeding in a single experiment.
- Achieved high-throughput analysis of anti-metastatic compound efficacy using NGS.
Conclusions:
- The developed platform provides a powerful tool for discovering novel anti-metastatic agents.
- DNA barcoding combined with NGS enables efficient and quantitative interrogation of compound libraries in vivo.
- This approach significantly advances the screening process for cancer metastasis inhibitors.
